Catalysts for Novo Nordisk Inc
40 tracked
Apr 20, 2026
drug shortage
Liraglutide Injection shortage — Novo Nordisk, Inc.
Novo Nordisk Inc
→
Feb 25, 2026
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Feb 24, 2026
approval
LIRAGLUTIDE — FDA approval
Novo Nordisk Inc
→
Jan 14, 2026
approval
LIRAGLUTIDE — FDA approval
Novo Nordisk Inc
→
Oct 15, 2025
approval
LIRAGLUTIDE — FDA approval
Novo Nordisk Inc
→
Oct 14, 2025
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Oct 14, 2025
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
May 28, 2025
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
May 28, 2025
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Apr 2, 2025
approval
LIRAGLUTIDE — FDA approval
Novo Nordisk Inc
→
Nov 1, 2024
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Nov 1, 2024
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Jul 10, 2023
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Apr 20, 2023
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Jun 15, 2022
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Jun 10, 2022
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Jun 10, 2022
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Dec 4, 2020
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Dec 4, 2020
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Dec 4, 2020
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Mar 25, 2020
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→
Nov 15, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Nov 15, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Aug 8, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Feb 27, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Feb 27, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Feb 27, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Feb 1, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Feb 1, 2019
approval
XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval
Novo Nordisk Inc
→
Dec 4, 2018
approval
SAXENDA (LIRAGLUTIDE) — FDA approval
Novo Nordisk Inc
→